In a GLP-1 market poised for rapid expansion and fierce competition, now is the critical moment for every stakeholder from pharma companies to investors to channel players to rethink their strategies, partnerships and competitive edge
The FDA declared the tirzepatide shortage resolved in late 2024 and the semaglutide shortage resolved in early 2025, and the grace periods for winding down compounding ended around May 2025
If your prescriber writes a prescription for compounded tirzepatide/niacinamide and documents a clinical justification, Empower can fill it
Many patients begin noticing changes within the first several weeks of treatment, while meaningful progress often continues over the following months
How much BPC-157 should I take for tendon recovery
However, it is important to consult with a healthcare professional if these side effects persist or worsen